Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Study ID: NCT05579366
Start Date: 2022-12-07
End Date: 2027-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

529

Intervention / Treatment

Rina-S

Carboplatin

Infinite

Pembrolizumab

Sponsor

Genmab

Source: clinicaltrials.gov

Share:
Add to list

Digital Art Therapy for Young Cancer Survivors

Study ID: NCT06789666
Start Date: 2025-04-07
End Date: 2027-04
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

15

Intervention / Treatment

ARTCan App

Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Study ID: NCT06904066
Start Date: 2025-08-13
End Date: 2029-04-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

86

Intervention / Treatment

Aldesleukin

cyclophosphamide

fludarabine phosphate

Individual Patient TCR-Transduced PBL

TruSight Oncology (TSO) 500

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Ribociclib and bicalutamide in ar+ Tnbc

Study ID: NCT03090165
Start Date: 2018-05-07
End Date: 2025-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

37

Intervention / Treatment

ribociclib

ribociclib

Bicalutamide

Sponsor

Kari Wisinski

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1/2 Trial of ADI-270 in ccRCC

Study ID: NCT06480565
Start Date: 2024-12-12
End Date: 2027-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

ADI-270

Fludarabine

Cyclophosphamide

Sponsor

Adicet Therapeutics

Source: clinicaltrials.gov

Share:
Add to list

Meaning-Centered Pain Coping Skills Training for Cancer Pain

Study ID: NCT05385965
Start Date: 2023-02-09
End Date: 2026-03-26
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

210

Intervention / Treatment

Meaning-Centered Pain Coping Skills Training

Sponsor

Duke University

Source: clinicaltrials.gov

Share:
Add to list

Improving Colonoscopy Surveillance for Patients with High Risk Colon Polyps

Study ID: NCT06376565
Start Date: 2023-11-08
End Date: 2027-11-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1680

Intervention / Treatment

Best Practice

Communication Intervention

Communication Intervention

Communication Intervention

Interview

Interview

Sponsor

Jonsson Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Study ID: NCT07021066
Start Date: 2025-07-30
End Date: 2027-05-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

120

Intervention / Treatment

BL-M05D1

Sponsor

SystImmune Inc.

Source: clinicaltrials.gov

Share:
Add to list

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

Study ID: NCT06441266
Start Date: 2025-05-08
End Date: 2027-08
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

16

Intervention / Treatment

Kerastat cream

M-PART Assessments via MyCap

Clinical Assessments

Feedback phone interview

Sponsor

Wake Forest University Health Sciences

Source: clinicaltrials.gov

Share:
Add to list

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Study ID: NCT06463665
Start Date: 2024-09-26
End Date: 2029-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

142

Intervention / Treatment

OlvimuULENGENE NanivaCirepvec

Platinum chemotherapy: carboplatin or cisplatin

Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC

Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab

Docetaxel

Sponsor

Genelux Corporation

Source: clinicaltrials.gov

Share:
Add to list